Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
CASI Pharmaceuticals Inc has a consensus price target of $8.67 based on the ratings of 3 analysts. The high is $12 issued by HC Wainwright & Co. on August 15, 2022. The low is $4 issued by HC Wainwright & Co. on April 9, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 9, 2025, May 15, 2024, and November 15, 2023, respectively. With an average price target of $7.33 between HC Wainwright & Co., there's an implied 309.68% upside for CASI Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/09/2025 | Buy Now | 123.46% | HC Wainwright & Co. | Sean Lee68% | $6 → $4 | Maintains | Buy | Get Alert |
05/15/2024 | Buy Now | 235.2% | HC Wainwright & Co. | Sean Lee68% | $12 → $6 | Maintains | Buy | Get Alert |
11/15/2023 | Buy Now | 570.39% | HC Wainwright & Co. | Sean Lee68% | $10 → $12 | Maintains | Buy | Get Alert |
08/14/2023 | Buy Now | 458.66% | HC Wainwright & Co. | Sean Lee68% | → $10 | Reiterates | Buy → Buy | Get Alert |
05/22/2023 | Buy Now | 458.66% | HC Wainwright & Co. | Sean Lee68% | → $10 | Reiterates | Buy → Buy | Get Alert |
11/16/2022 | Buy Now | 458.66% | BTIG | Justin Zelin40% | $21 → $10 | Maintains | Buy | Get Alert |
11/15/2022 | Buy Now | 458.66% | HC Wainwright & Co. | Sean Lee68% | $12 → $10 | Maintains | Buy | Get Alert |
08/15/2022 | Buy Now | 570.39% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $3 → $12 | Maintains | Buy | Get Alert |
06/03/2022 | Buy Now | 1073.18% | BTIG | Justin Zelin40% | $4 → $21 | Maintains | Buy | Get Alert |
05/16/2022 | Buy Now | 67.6% | HC Wainwright & Co. | Sean Lee68% | $4 → $3 | Maintains | Buy | Get Alert |
The latest price target for CASI Pharmaceuticals (NASDAQ:CASI) was reported by HC Wainwright & Co. on April 9, 2025. The analyst firm set a price target for $4.00 expecting CASI to rise to within 12 months (a possible 123.46% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for CASI Pharmaceuticals (NASDAQ:CASI) was provided by HC Wainwright & Co., and CASI Pharmaceuticals maintained their buy rating.
There is no last upgrade for CASI Pharmaceuticals
There is no last downgrade for CASI Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $6.00 to $4.00. The current price CASI Pharmaceuticals (CASI) is trading at is $1.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.